Clinical Summary
Clinical Summary: Triggers and Characteristics of Brain Zaps According to the Findings of an Internet Questionnaire
Patients stopping or reducing antidepressants sometimes report “brain zaps,” but these symptoms are often poorly characterized and easy to dismiss. This study gives clinicians concrete features to recognize—including links to antidepressant half-life, eye or head movement triggers, and substantial functional burden—so the complaint can be identified and managed more effectively.
Design
an anonymous questionnaire was placed online in Google Forms
N
3,141
Population
The respondents had to state that they were aged ≥ 18 years
Duration
The questionnaire was open to responses between June 2016 and February 2018
Key Findings
- Zap onset latency differed significantly by antidepressant half-life group, with Kruskal-Wallis testing showing P < .0001, χ2 = 144.6; fluoxetine and vortioxetine had longer latency than the other 2 groups (P < .0001), and medium half-life drugs also had longer latency than paroxetine and (des)venlafaxine (P < .0001).
- Eye or head movement was the most commonly reported trigger: 1,012 respondents identified eye or head movements, and 203 more reported unspecified “movement,” for a total of 1,215 responses that specifically, or possibly, referred to movement of eyes as a trigger.
- Brain zaps often remained active and clinically burdensome: 2,103 of 2,267 respondents (93%) reported that they were still having brain zaps at the time of completing the questionnaire, and 17% rated the quality-of-life impact as “overwhelming.”
- Restarting the original antidepressant was commonly attempted and usually helpful: 1,468 respondents restarted the medication versus 779 who did not, and among those who restarted, it helped in 682 cases versus 86 cases in which it did not.
- Fast medication changes were common precipitants, but slow tapering was not fully protective: 788 cases occurred during a gradual weaning, 528 during a rapid weaning, 909 after sudden discontinuation, and 844 when respondents skipped a dose.
Clinical Bottom Line
Brain zaps are a recognizable antidepressant discontinuation phenomenon, not a vague nonspecific complaint. In practice, eye-movement-triggered symptoms after dose reduction or missed doses should prompt clinicians to consider antidepressant withdrawal and manage it with serotonergic reinstatement or switching strategies rather than dismissing the symptom.
Practice Implications
- Ask directly whether symptoms are triggered by lateral eye or head movements; 1,012 respondents reported eye or head movement triggers, making this a useful bedside clue for identifying true brain zaps.
- When brain zaps emerge after antidepressant reduction, consider reinstating the same antidepressant; among respondents who restarted medication, 682 reported benefit versus 86 who did not.
- If switching is needed, a serotonergic antidepressant may be more useful than nonserotonergic options; the article notes that fluoxetine was the most frequent second serotonergic agent and that bupropion was effective in only 8% of respondents.
- Do not minimize the symptom burden or assume slow tapering eliminates risk; 17% described the impact as “overwhelming,” 2,103 of 2,267 (93%) were still symptomatic at survey completion, and 788 cases still occurred during a gradual weaning.
